Reporting from: – 4th European Breast Cancer Conference, March 16-20, 2004, Hamburg – 6th International Symposium on Hodgkin’s Lymphoma – 16th EORTC-NCI-AACR Symposium on Molec
Reporting from:
– 4th European Breast Cancer Conference, March 16-20, 2004, Hamburg
– 6th International Symposium on Hodgkin’s Lymphoma
– 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, September 28-October 1, 2004, Geneva
– Journal of Clinical Oncology
– New England Journal of Medicine
– Lancet
– British Journal of Cancer
In this edition:
Ian Smith questions the routine use of radiotherapy for patients with breast cancer treated with lumpectomy in the light of two publications and his editorial in the New England Journal of Medicine.
The molecularly targeted drug cetuximab could be reversing irinotecan resistance in patients with metastatic colorectal cancer, according to Naureen Starling and Eric van Cutsem.
The usefulness of adjuvant chemotherapy in patients with stage II colon cancer is discussed by George Canellos and Gordon McVie following publications in the Journal of Clinical Oncology.
An analog of thalidomide shows promise for treating patients with relapsed, refractory myeloma, according to Steven Schey.
In a group of patients with hormone-refractory metastatic prostate cancer, Alison Birtle has found a non-taxane regimen to be as promising as the recent results using docetaxel.
Related Episodes
Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer
Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective following primary systemic therapy for early breast cancer patients. This approach allows for tailored treatment, potentially reducing side effects without compromising low recurrence rates. The study provides crucial long-term evidence supporting individualized radiotherapy strategies.
Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy
At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal
Elisa Agostinetto MD; 2026 EBCC: Circulating Tumor DNA Trumps Clinical Prognostic Markers After Neoadjuvant Therapy for Patients with Early Breast Cancer
Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast cancer patients after neoadjuvant therapy. This research supports ctDNA for post-neoadjuvant risk st